Search Medical Condition
Please enter condition
Please choose location

La Grange, Illinois Clinical Trials

A listing of La Grange, Illinois clinical trials actively recruiting patient volunteers.

RESULTS

Found (358) clinical trials

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

This study will be a randomized phase III for patients with newly diagnosed co-deleted 1p/19q anaplastic glioma or high risk low grade glioma. The trial will only enroll patients with 1p/19q co-deletion. This study includes two arms as described in the "Arms" section. A dynamic allocation procedure will be used ...

Phase

0.0 miles

Learn More »

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

OUTLINE: This is a 2-part, multicenter, randomized study. Patients are stratified according to gender, weight loss 6 months prior to study entry ( 5% of body weight vs > 5% of body weight), ECOG performance status (0 vs 1 vs 2), radiotherapy technique (intensity-modulated radiotherapy vs 3-dimensional conformal radiotherapy), radiotherapy ...

Phase

0.0 miles

Learn More »

Dialogue Around Respiratory Illness Treatment

Antibiotic prescribing for childhood ARTIs, including acute otitis media (AOM), sinusitis, bronchitis, upper respiratory infection (URI), and pharyngitis is common in the United States. An estimated 31.7 million visits for respiratory conditions result in antibiotic prescriptions annually, accounting for >70% of outpatient visits during which antibiotics are prescribed to children. ...

Phase N/A

0.0 miles

Learn More »

Coordinated Oral Health Promotion (CO-OP) Chicago

Dental caries is the most common chronic disease of childhood; an estimated 28% of children nationally aged 5 years and below have untreated dental disease. Pediatric dental caries are associated with pain, more severe infections, malnutrition, speech difficulties, poor school performance, cosmetic problems, and an overall lower quality of life. ...

Phase N/A

2.33 miles

Learn More »

OPTIMIZE IDE for the Treatment of ACS

Indication for use: "The Svelte DES is indicated for improving coronary luminal diameter in patients with symptomatic heart disease, including patients with non-ST elevation MI due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent length with a reference vessel ...

Phase N/A

3.19 miles

Learn More »

Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS

Multicenter, multiple dose study to examine the effect of H.P. Acthar Gel (repository corticotropin injection) in adult subjects with idiopathic focal segmental glomerulosclerosis (FSGS) who have failed to achieve remission with, or who are intolerant of, 1 or more previous immunosuppressive therapies.

Phase

3.27 miles

Learn More »

Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for ICD therapy and programmed according to current guidance of higher rate cut-offs and therapy delays. The time to first all-cause shock will be tested in subjects with standard therapy (ATP and shocks) ...

Phase N/A

3.27 miles

Learn More »

Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer

PRIMARY OBJECTIVES: I. Assess the efficacy of either single agent olaparib or the combination of cediranib (cediranib maleate) and olaparib, as measured by progression free survival (PFS), as compared to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer. SECONDARY OBJECTIVES: I. Assess ...

Phase

3.27 miles

Learn More »

MultiPoint Pacing Post Market Study

Any patient who received a market approved SJM Quadra Allure MP, Quadra Assura MP, or newer SJM CRT MP device is eligible for enrollment in the study. MultiPoint Pacing (MPP) programming guidance will be specified in the protocol. Patients will be followed for 12 months after implant. Data will be ...

Phase N/A

3.27 miles

Learn More »